Show simple item record

dc.contributor.authorClamp, Andrew R
dc.contributor.authorJayson, Gordon C
dc.date.accessioned2009-10-05T15:08:21Z
dc.date.available2009-10-05T15:08:21Z
dc.date.issued2002-08
dc.identifier.citationThe clinical development of the bryostatins. 2002, 13 (7):673-83 Anticancer Drugsen
dc.identifier.issn0959-4973
dc.identifier.pmid12187323
dc.identifier.urihttp://hdl.handle.net/10541/83568
dc.description.abstractThe bryostatins are a group of novel macrocyclic lactones derived from the marine bryozoan, Bugula neritina. In vitro evidence indicates that their main mechanism of action is modulation of protein kinase C (PKC) activity. Phase I studies suggested significant antineoplastic activity against several tumor types and defined the main dose-limiting toxicity as myalgia. Bryostatin-1 has subsequently been investigated extensively in phase II clinical trials as a single agent, although trial design has been hampered by lack of human pharmacokinetic data. Results have been generally disappointing but in vitro and animal data suggests an important role for bryostatin-1 in combination with cytotoxic agents. Preliminary results of phase I studies support these observations but further work needs to be done to define the future role of the bryostatins in the clinic.
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshAnimals
dc.subject.meshAntineoplastic Agents
dc.subject.meshBryostatins
dc.subject.meshClinical Trials as Topic
dc.subject.meshClinical Trials, Phase I as Topic
dc.subject.meshClinical Trials, Phase II as Topic
dc.subject.meshHumans
dc.subject.meshImmunotherapy, Adoptive
dc.subject.meshLactones
dc.subject.meshMacrolides
dc.subject.meshNeoplasms
dc.titleThe clinical development of the bryostatins.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Manchester M20 4BX, UK. aclamp@picr.man.ac.uken
dc.identifier.journalAnticancer Drugsen
html.description.abstractThe bryostatins are a group of novel macrocyclic lactones derived from the marine bryozoan, Bugula neritina. In vitro evidence indicates that their main mechanism of action is modulation of protein kinase C (PKC) activity. Phase I studies suggested significant antineoplastic activity against several tumor types and defined the main dose-limiting toxicity as myalgia. Bryostatin-1 has subsequently been investigated extensively in phase II clinical trials as a single agent, although trial design has been hampered by lack of human pharmacokinetic data. Results have been generally disappointing but in vitro and animal data suggests an important role for bryostatin-1 in combination with cytotoxic agents. Preliminary results of phase I studies support these observations but further work needs to be done to define the future role of the bryostatins in the clinic.


This item appears in the following Collection(s)

Show simple item record